FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Dominik Paul Modest,Uwe M. Martens,Jorge Riera-Knorrenschild,Jobst Greeve,Axel Florschütz,Swen Wessendorf,Thomas Jens Ettrich,Stephan Kanzler,Dominik Nörenberg,Jens Ricke,Max Seidensticker,Swantje Held,Petra Buechner-Steudel,Jens Atzpodien,Volker Heinemann,Thomas Seufferlein,Andrea Tannapfel,Anke Reinacher-Schick,Michael Geissler

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

2019

Dominik Paul Modest
Uwe M. Martens
Jorge Riera-Knorrenschild
Jobst Greeve
Axel Florschütz
Swen Wessendorf
Thomas Jens Ettrich
Stephan Kanzler
Dominik Nörenberg
Jens Ricke
Max Seidensticker
Swantje Held
Petra Buechner-Steudel
Jens Atzpodien
Volker Heinemann
Thomas Seufferlein
Andrea Tannapfel
Anke Reinacher-Schick
Michael Geissler

PURPOSEThis trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, op...

Keywords:

Irinotecan
Folinic acid
Pathology
Oxaliplatin
Panitumumab
Internal medicine
Chemotherapy
Oncology
Fluorouracil
Colorectal cancer
Medicine
FOLFOXIRI
Wild type

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations